Previous close | 0.1913 |
Open | 0.0000 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 18,488 |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2310 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents Paris, France, January 27, 2023 – 6.00 pm CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that an Extraordinary General Meeting of the Company will be held on Wednesday February 15, 2023, at 2.00 pm CET at th
Pixium Vision convenes an Extraordinary General Meeting of Shareholders on February 15, 2023 Paris, France, January 20, 2023 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that it will hold an extraordinary general meeting of shareholders (EGM) at 14:00 CET on February 15, 2023 at Pixium Vision’s headquarter of
Pixium Vision announces peer-reviewed publications demonstrating the potential of the Next Generation PRIMA implant to restore vision at five times higher resolution than current implant New implants leverage existing PRIMA design with significant increase in spatial resolutionPotential to restore vision to levels sufficient for face recognition and reading smaller fonts: 20/100 with no magnification and up to 20/20 with electronic magnificationData on the new implants published in top-tier scie